Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: GlobeNewswire
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction. “This is a historic moment for our company and for the patients we serve, as we fulfill our promise to tra
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? [Yahoo! Finance]Yahoo! Finance
- Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswire
- Cytokinetics (NASDAQ:CYTK) was given a new $95.00 price target on by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.MarketBeat
- Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic CardiomyopathyGlobeNewswire
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 12/19/25 - Form 8-K
- 12/16/25 - Form 4
- 12/12/25 - Form 8-K
- CYTK's page on the SEC website